Romosozumab improves bone mineral density (BMD) in men with osteoporosis, according to results from the BRIDGE (placeBo-contRolled double-blind study evaluatIng the efficacy anD safety of romosozumab in treatinG mEn with osteoporosis) trial reported online June 20, 2018 in The Journal of Clinical Endocrinology and Metabolism. One year treatment with 210 mg SC QM romosozumab increased spine and hip BMD compared with placebo and was well tolerated.